| Literature DB >> 33590718 |
Ban Chen1, Xican Li1, Jie Liu2, Yuling Li1, Wanjian Dai1, Yingci Chen1, Dongfeng Chen3.
Abstract
The search for safe and effective ferroptosis-inhibitors has become an important topic. Geraniin, an ellagitannin bearing hexahydroxydiphenoyl (HHDP) and dehydrohexahydroxydiphenoyl (DHHDP) groups, was observed to inhibit erastin-induced ferroptosis in bone marrow-derived mesenchymal stem cells (bmMSCs). To determine the mechanism, geraniin was further analyzed using UV-vis spectra and several colorimetric assays, where its IC50 values were always much lower than that of the Trolox positive control. When interacted with several free radicals, geraniin gave no radical adduct formation (RAF) peak in the ultra-performance liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. In conclusion, geraniin exhibits ferroptosis-inhibitory potential towards erastin-treated bmMSCs; such potential may mainly stem from its strong lipid peroxidation (LPO)-inhibition, Fe2+ -chelating, and antioxidant actions. Geraniin gives neither dimer nor radical adduct, owing to the bulky HHDP (or DHHDP) group; thus, it is considered as a safe and effective ferroptosis-inhibitor.Entities:
Keywords: ellagitannin; ferroptosis; geraniin; lipid peroxidation reactions; mesenchymal stem cells
Year: 2021 PMID: 33590718 PMCID: PMC8340064 DOI: 10.1002/open.202000255
Source DB: PubMed Journal: ChemistryOpen ISSN: 2191-1363 Impact factor: 2.630
Figure 1The structure of geraniin
Figure 2The inhibitory effect of geraniin on erastin‐induced ferroptosis in bmMSCs: (A) C11‐BODIPY assay. (B) CCK‐8 assay; the control group (I) was cultured in medium only, while the ferroptosis model group (II) was treated with erastin. The sample group was damaged by erastin and then treated with 0.3 (III) and 3.1 μM (IV) geraniin. Each value is expressed as the mean±SD, n=3; *, p<0.05, significant difference vs the model group. (C) Flow cytometry assay; the assay was conducted to distinguish live cells (Q4), necrotic cells (Q1), early apoptotic cells (Q3), and late apoptotic cells (Q2). The experiment was performed with three different batches of cells and each batch was tested in triplicate.
IC50 values (μM) of geraniin in antioxidant colorimetric assays.
|
Assays |
Geraniin [μM] |
Positive controls |
|
Ratio |
|---|---|---|---|---|
|
|
|
Trolox [μM] |
BHA [μM] |
|
|
LPO‐inhibition |
53.8±6.5[b] |
173.7±22.4[c] |
6.2±0.1[a] |
3.23 |
|
Fe2+‐chelating |
60.1±6.8[a] |
131.5±17.9[b], * |
No applicable |
2.19 |
|
•O2 −‐scavenging |
1308.4±307.3[a] |
7503.5±1793.8[b] |
24808.4±5513.7[c] |
5.73 |
|
Cu2+‐reducing |
13.0±0.4[a] |
130.2±5.2[b] |
137.8±15.6[b] |
10.02 |
|
Fe3+‐reducing |
20.2±0.4[a] |
76.4±1.6[b] |
337.8±2.0[c] |
3.78 |
|
Folin‐Ciocalteu‐reducing |
14.8±1.0[a] |
108.8±3.1[b] |
95.9±1.3[b] |
7.35 |
|
PTIO•‐scavenging (pH 4.5) |
113.1±1.8[a] |
288.6±26.7[b] |
283.4±71.1[b], ** |
2.55 |
|
PTIO•‐scavenging (pH 7.4) |
67.1±9.1[a] |
444.7±34.8[c] |
255.8±54.6[b], ** |
6.63 |
|
DPPH•‐scavenging |
4.4±0.4[a] |
19.4±1.0[b] |
32.0±4.0[c] |
4.41 |
|
|
| |||
The IC50 value (in μM) is defined as the final concentration of 50% radical inhibition or relative reducing/chelating power, calculated by linear regression analysis, and expressed as the mean±SD (n=3) (Table S1). Linear regression was analyzed by Origin 2017 professional software. The IC50 values with different superscripts ([a], [b], or [c]) in the same row, are significantly different (p<0.05). Trolox is the positive control (*, the positive control is sodium citrate instead of Trolox; **, the positive control is vitamin C instead of butylated hydroxyanisole (BHA)). The dose‐response curves are listed in Figures S5–S14. Abbreviations: LPO: lipid peroxidation; PTIO: 2‐phenyl‐4,4,5,5,‐tetramethylimidazoline‐1‐oxyl 3‐oxide; DPPH: 1,1‐diphenyl‐2‐picrylhydrazyl. Ratio is defined as IC50, Trolox/IC50, geraniin.